Previous 10 | Next 10 |
Cellectar Biosciences (NASDAQ: CLRB ): Q1 GAAP EPS of -$0.42 misses by $0.07 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
FLORHAM PARK, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the three ...
Cellectar Biosciences (NASDAQ: CLRB ): FY GAAP EPS of -$1.84 beats by $0.05 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
FLORHAM PARK, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year...
Tivity Health (NASDAQ: TVTY ) -39% on Q4 earnings . More news on: Tivity Health, Inc., Six Flags Entertainment Corporation, BioXcel Therapeutics, Inc., Stocks on the move, Read more ...
Gainers: Myomo (NYSEMKT: MYO ) +48% . More news on: Myomo, Inc., Enphase Energy, Inc., Altisource Asset Management Corporation, Stocks on the move, , Read more ...
Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) slumps 23% premarket on increased volume in reaction to results from a Phase 2 clinical trial, CLOVER-1 , evaluating lead candidater CLR 131 in patients with relapsed/refractory B-cell lymphomas. More news on: Cell...
42.8% ORR in multiple myeloma at the 75mCi total body dose 42.0% ORR and 11% CRR in all non-Hodgkin’s lymphoma (NHL) patients 100% ORR seen in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia (LPL/WM) patients 76.7% of the multiple myeloma ...
Are These The Best Stocks To Trade Before The End Of February 2020? It goes without saying that investing in penny stocks comes with a certain level of risk. But at the same time, these cheap stocks can often generate substantial returns in a short period of time. Over the years, plenty of...
The following slide deck was published by Cellectar Biosciences, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...